The decision to centre emerging investigators rather than established luminaries is itself a statement about how science should evolve. The authors argue that researchers early in their careers are uniquely positioned to challenge prevailing assumptions, adopt interdisciplinary approaches and redirect priorities that may have calcified over decades. The resulting collection of perspectives spans an unusually wide technical range, from neoadjuvant immunotherapy in colorectal cancer to somatic mosaicism in healthy tissues, from the nervous system’s role in tumour progression to artificial intelligence models that predict cellular responses to genetic perturbation. Together, the six contributions sketch a research agenda that is more integrated, more prevention-focused and more computationally ambitious than anything the field has attempted before.

One thread running through the article is the remarkable maturation of cancer immunotherapy, particularly when treatment is moved earlier in the disease course. Myriam Chalabi, a medical oncologist and physician scientist at the Netherlands Cancer Institute in Amsterdam, has built her research programme around immunotherapy delivered in the neoadjuvant setting, using novel treatment combinations within innovative trial designs. The clinical evidence underpinning this shift is striking: recent work has demonstrated neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers, while separate research has shown that non-operative management of mismatch repair deficient tumours can produce durable responses, in some cases allowing patients with rectal cancer to avoid surgery entirely. These results suggest that the immune system, when engaged before a tumour has been removed, can eliminate disease that conventional staging would consider established, and they raise the prospect of organ-preserving treatment as a realistic goal rather than an aspirational one.

Yet immunotherapy has also exposed the limits of tumour-centric thinking, and several of the authors argue that the next 25 years must focus on the host as much as the tumour. James L. Reading, an associate professor of cancer immunology at UCL who leads the Pre-cancer Immunology Laboratory, studies T cell-driven cancer interception — the idea of detecting and eliminating tumours before they become clinically invasive. His work builds on the discovery that reservoirs of stem-like CD8-positive T cells in tumour-draining lymph nodes sustain ongoing antitumor immune responses, and that conventional type I dendritic cells maintain pools of proliferative, tumour-antigen-specific TCF1-positive CD8-positive T cells in those same nodes. Understanding how these immune reservoirs are established and maintained during pre-invasive disease, he argues, could transform early detection from passive imaging into active, immune-guided interception, catching malignancy at a stage when cure rates approach certainty.

The genomic dimension of this preventive agenda is developed most fully by Tim H. H. Coorens, a group leader at the European Bioinformatics Institute who studies how somatic mutations accumulate in normal cells. Twenty-five years ago, cancer genomes were largely studied in isolation from the tissues that produced them. Today, it is clear that essentially every cell in the body accrues mutations over a lifetime, and that clones of mutant cells — some harmless, some pre-malignant — expand and compete in otherwise healthy tissue. Coorens contributed to the Somatic Mosaicism Across Human Tissues network, an effort to catalogue this variation systematically, and recent analyses have shown that age itself can distinguish selective clonal expansion from simple mutational causation in cancer genomes. Meanwhile, the real-world clinical utility of tumour whole-genome sequencing in solid cancers has now been demonstrated at scale, suggesting that comprehensive genomic profiling is moving from research luxury to standard of care. The conceptual shift is profound: cancer becomes not a foreign invader but one possible endpoint of a lifelong evolutionary process, and the levers for prevention may lie in the dynamics of normal tissue.

Perhaps the most visually striking frontier is cancer neuroscience. Leanne Li, a group leader at the Francis Crick Institute in London, combines cancer genetics with neurotechnologies to decipher the logic of interactions between tumours and the nervous system in mouse models. The field’s roots reach back more than a century to observations of nerves within tumours made using methylene blue vital staining, but modern cancer neuroscience has exploded in the past decade. Recent single-neuron sequencing has revealed how individual neurons are reprogrammed by pancreatic cancer, and comprehensive reviews have mapped the past, present and future of the discipline. Li also leads InteroCANCEption, a multidisciplinary team funded by Cancer Grand Challenges to tackle the broader question of how interoception — the body’s sensing and regulation of its own internal signals, a concept elaborated in modern neuroscience — shapes tumour initiation, growth and response to therapy. If tumours co-opt neural circuitry the way they co-opt blood vessels, then neuromodulatory drugs already approved for other conditions could become unexpected additions to the oncology arsenal.

Resistance to therapy, the stubborn core of cancer mortality, is the focus of Shensi Shen, associate professor at West China Hospital, Sichuan University. His work centres on drug-tolerant persister cells — a subpopulation of cancer cells that survives initial treatment not through genetic mutation but through reversible shifts in cell state. Reviews have traced the journey of persister cell biology from basic questions to clinical opportunities, and single-cell analyses have shown that genetically homogeneous cancer cells can diverge into multiple distinct clonal fates when exposed to the same drug. Shen’s particular interest is in layered translational control: the regulation of how messenger RNA is decoded into protein, which allows cancer cells to deploy hidden protein functions and switch states under therapeutic pressure. Because these transitions are non-genetic, they are also potentially reversible, which makes the persister state an attractive target for combination strategies designed to block the escape routes that tumours use to survive targeted therapy and immunotherapy alike.

Underpinning all of these biological questions is a computational revolution, examined by Ewa Szczurek, associate professor at the University of Warsaw and director of the Institute of AI for Health at Helmholtz Munich. Szczurek develops artificial intelligence models for molecular biology and medicine, and her perspective is notably sober about the current state of the field. While foundation models promise to predict how cells respond to genetic and pharmacological perturbations — an ambition exemplified by recent preprint work on state-based prediction of cellular responses — independent evaluations have shown that deep-learning-based gene perturbation effect prediction does not yet outperform simple linear baselines in many settings. Her message is that the next 25 years of AI in cancer research will be defined not by model size but by data quality, experimental validation and careful benchmarking. If the field heeds that warning, machine learning could genuinely accelerate target discovery and personalised treatment; if it does not, hype risks outrunning biology.

Woven together, the six perspectives describe a field in mid-revolution. The tumour-as-isolated-entity model is giving way to a systems view in which cancer is embedded in the evolutionary dynamics of normal tissues, the immune landscape of pre-invasive disease, the neural circuitry of the host body and the non-genetic plasticity of individual cells. Clinical paradigms are shifting in parallel: treatment is moving earlier, surgery is sometimes becoming optional, and molecular residual disease monitoring — exemplified by analyses of adjuvant osimertinib in resected EGFR-mutated lung cancer — is becoming a guide for post-operative decisions. The anniversary article also translates premalignant biology into strategies for intercepting non-small-cell lung cancer, illustrating how laboratory insight can be converted directly into prevention trials.

What emerges most clearly is a demand for interdisciplinarity as a structural principle rather than a slogan. The authors themselves embody it: a clinician designing immunotherapy trials, a bioinformatician decoding mutation accumulation, a neuroscientist engineering tools to interrogate tumour-nerve crosstalk, an immunologist chasing T cells before invasion, a molecular biologist tracking protein-level resistance and a computer scientist stress-testing the field’s newest models. Their collective wager is that the major killers of the next quarter-century will not be defeated by any single breakthrough but by the deliberate integration of genomics, immunology, neuroscience, developmental biology and computation — and by the willingness of a new generation to ask questions their predecessors did not think to ask.

Subject of Research: Emerging investigators' perspectives on the future priorities of cancer research over the next 25 years

Article Title: The next 25 years of cancer research: emerging perspectives and priorities

Article References: Chalabi, M., Coorens, T. H. H., Li, L., Reading, J. L., Shen, S., & Szczurek, E. (2026). The next 25 years of cancer research: emerging perspectives and priorities. Nature Reviews Cancer. https://doi.org/10.1038/s41568-026-00975-3

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00975-3

Keywords: cancer research, Nature Reviews Cancer, immunotherapy, neoadjuvant therapy, somatic mosaicism, cancer neuroscience, cancer interception, drug-tolerant persister cells, tumour heterogeneity, whole-genome sequencing, artificial intelligence, early detection

The clinical potential of neoantigen vaccines lies in their ability to harness the immune system’s specificity, targeting mutated peptides absent in normal tissues, thereby minimizing off-target effects and immune tolerance. Early-phase clinical trials have painted an encouraging picture, demonstrating that vaccination with personalized neoantigens can stimulate robust and sustained T cell immunity. Notably, these T cell responses are not transient but instead exhibit remarkable longevity, sometimes persisting for years, a finding that raises hope for long-term tumor surveillance and control. Such durable immunity is the foundation for the ambition to develop neoantigen vaccines that not only shrink tumors initially but maintain remission through ongoing immune vigilance.

A cornerstone of current neoantigen vaccine development is the choice of delivery platform, an aspect as critical as antigen selection itself. Among the various platforms explored, messenger RNA (mRNA) vaccines have emerged as a frontrunner, leveraging breakthroughs originally conceived for oncology but gaining global attention during the SARS-CoV-2 pandemic. The adaptability, rapid manufacturability, and potent immunogenicity of mRNA vectors have demonstrated significant advantages over traditional vaccine techniques. mRNA vaccines avoid risks associated with viral vectors or synthetic peptides and can encode multiple neoantigen epitopes simultaneously, ensuring a broad immune attack. However, despite these promising features, the optimal vaccine platform remains unsettled, as no single approach has undergone comprehensive head-to-head comparison in clinical contexts.

One key challenge in perfecting neoantigen vaccine efficacy lies in enhancing immunogenicity, particularly given the immunosuppressive milieu that characterizes many solid tumors. While mRNA vaccines utilize lipid nanoparticles (LNPs) for delivery, these lipid-based formulations themselves appear to have adjuvant properties that may potentiate immune activation beyond merely ferrying mRNA into cells. The capacity of lipids to stimulate innate immune receptors and promote antigen-presenting cell maturation suggests that leveraging such formulations for other vaccine modalities, including synthetic peptides, could unlock improvements in immune responses. This hypothesis invites a reexamination of delivery strategies with an eye toward integrated vaccine design, combining antigen presentation, innate stimulation, and tailored immune modulation.

Beyond delivery vehicles, refining neoantigen selection algorithms is an active frontier. Advances in HLA binding prediction now incorporate not only peptide affinity but broader immunopeptidomic features, including peptide processing, presentation likelihood, and T cell receptor repertoires. Machine learning models, trained on extensive immunological datasets, are increasingly capable of filtering out less immunogenic candidates, enabling prioritization of neoantigens most likely to elicit meaningful anti-tumor immunity. Additionally, personalized neoantigen vaccines can be customized further by considering the patient’s tumor microenvironment, somatic mutation quality, and tumor heterogeneity, all of which influence immunotherapy outcomes.

The enduring challenge of tumor immune evasion remains a formidable barrier. Tumors employ numerous mechanisms to escape immune detection, including antigen loss, MHC downregulation, and immunosuppressive cytokine milieu, which can blunt vaccine-induced responses. Multimodal strategies combining neoantigen vaccines with checkpoint inhibitors or cytokine therapies are under intense investigation, aiming to synergize the activation and sustaining of antitumor T cells. Early clinical trial data suggest that such combinations can amplify therapeutic benefit while maintaining manageable safety profiles, substantiating a paradigm where personalized vaccination becomes part of a broader immunotherapy arsenal.

Another exciting avenue in neoantigen vaccine innovation involves the refinement of delivery kinetics and localization. Nanoparticle formulations that target lymph nodes—the hub of immune activation—show promise in enhancing antigen presentation efficiency and T cell priming. Controlled-release vehicles and scaffold-based platforms seek to extend the duration of neoantigen exposure, potentially fostering the development of memory T cell populations critical for long-term tumor control. These advances reflect a growing appreciation for the immunological microenvironments that dictate vaccine potency.

The scalability of neoantigen vaccine production also remains a core consideration for translation from experimental therapy to widespread clinical application. mRNA vaccines have notable advantages here, with manufacturing pipelines that can rapidly adapt to individual neoantigen sequences, supported by the infrastructure established during the COVID-19 crisis. Nonetheless, the complexity of tumor mutational landscapes and personalized vaccine design mandates continued investments in automation, bioinformatics, and quality control to ensure affordability and accessibility.

From a regulatory perspective, neoantigen vaccines challenge traditional frameworks because each patient receives a unique therapeutic formulation. Regulatory agencies and developers are collaborating to establish standards for vaccine characterization, release criteria, and clinical trial designs that accommodate this personalized approach. Real-world data and adaptive trial methodologies will be crucial to demonstrating efficacy and safety at scale, accelerating approval pathways.

Despite the early promise, meaningful clinical impact of neoantigen vaccines has yet to be conclusively demonstrated in large randomized trials, leaving open questions about their ultimate role in cancer therapy. Tumor types with high mutational burdens, such as melanoma and certain lung cancers, have shown heightened response rates, possibly due to the increased abundance of neoepitopes. However, for low-mutational burden tumors or those with complex immunosuppressive features, combination treatments or novel vaccine formulations may be essential to unlock clinical benefit.

An emerging area of interest is the potential for neoantigen vaccines to act not only therapeutically but preventively, targeting pre-malignant lesions or minimal residual disease states. This paradigm shift could leverage the specificity and durability of T cell immunity to intercept cancer development at its earliest stages, translating into improved patient outcomes and reduced treatment burdens. Harnessing liquid biopsies and circulating tumor DNA for dynamic neoantigen identification will be critical enablers of this futuristic vision.

In conclusion, the intersection of genomics, bioinformatics, and immunology is rapidly transforming neoantigen vaccine development into a promising pillar of personalized oncology. Ongoing technological advances in sequencing, epitope prediction, delivery platforms, and immunomodulation herald a new wave of innovation that could overcome current limitations and yield impactful cancer immunotherapies. As the field matures, rigorous clinical validation, standardization, and integration into multimodal treatment regimens will be key to fully realize the potential of neoantigen vaccines to improve patient survival and quality of life.

The journey from early clinical optimism to widespread therapeutic adoption involves navigating scientific, technical, and regulatory challenges with equal rigor. Collaboration across disciplines, institutions, and industry stakeholders will be essential to accelerate progress. With the tools of precision medicine in hand, the promise of vaccines that empower the immune system to recognize and eradicate the heterogeneous landscape of tumor mutations may soon become a clinical reality, reshaping standards of cancer care in the decades to come.

Subject of Research: Neoantigen cancer vaccines and their clinical development, including advances in genomic sequencing, epitope prediction, delivery platforms, and immunogenicity enhancement.

Article Title: The promises and challenges of neoantigen cancer vaccines

Article References:
Ott, P.A. The promises and challenges of neoantigen cancer vaccines.
Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03018-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-026-03018-2

Mismatch repair (MMR) is a fundamental cellular mechanism that corrects replication errors that occur during DNA synthesis. In individuals with CMMRD, mutations in key MMR genes such as MLH1, MSH2, MSH6, or PMS2 completely abolish the ability to rectify mismatched nucleotides. This failure results in a rapid accumulation of mutations, elevating the risk of early-onset tumors. However, despite the known clinical significance of CMMRD, the specific mutagenic processes shaping the tumor mutational patterns remained poorly characterized until now. The team employed cutting-edge genomic sequencing and computational modeling methods to dissect these complex mutational signatures with remarkable precision.

Their findings revealed an intricate interplay between endogenous and exogenous mutagenic forces, whose combined effects sculpt the evolving tumor genome. Endogenous processes such as spontaneous deamination and oxidative damage appear amplified in the absence of functional mismatch repair. The researchers identified distinctive mutational signatures characterized by a high burden of insertion-deletion mutations as well as base substitutions, which are hallmarks of defective MMR. These patterns differ significantly from sporadic tumors without mismatch repair deficiency, underscoring the unique evolutionary pressures within CMMRD tumors.

One of the most striking aspects uncovered by the study is the evidence for ongoing mutagenesis driven by DNA polymerase slippage events in microsatellite regions. Microsatellites are repetitive DNA sequences that are particularly prone to replication errors. In the context of defective MMR, these errors go unchecked, fostering genomic instability and facilitating rapid tumor evolution. By mapping these microsatellite instability (MSI) events alongside single nucleotide variant profiles, the researchers successfully linked specific mutational processes to the clonal architecture of tumors, providing a window into their developmental history.

Furthermore, the study delved deeply into the contribution of exogenous mutagens in shaping CMMRD-associated tumor genomes. Exposure to environmental factors such as ultraviolet radiation, tobacco carcinogens, and dietary mutagens leaves characteristic imprints—mutational footprints—on DNA. Surprisingly, even in the heightened mutational landscape driven by genetic defects, these external influences remain discernible, suggesting that lifestyle and environmental exposures can further modulate tumor evolution in these vulnerable patients. This raises compelling questions about potential intervention strategies that reduce exposure to mutagenic agents to slow tumor progression.

On the technical front, the researchers utilized ultra-deep whole-genome sequencing techniques coupled with novel bioinformatic algorithms capable of deconvoluting overlapping mutational signatures. The ability to disentangle contributions from various mutagenic sources in a highly heterogeneous tumor milieu represents a significant methodological leap. The study’s analytic framework allowed for temporal resolution of mutational events, charting how certain mutagenic processes dominate at different tumor stages. These insights hold promise for refining molecular diagnostics and tailoring therapies sensitive to the underlying mutational processes.

Another compelling aspect of the investigation lies in the identification of previously unrecognized mutational signatures specific to CMMRD tumors. These novel signatures provide clues to biochemical events and enzymatic dysfunctions beyond classical mismatch repair failure. For example, patterns attributed to aberrant activity of APOBEC cytidine deaminases were observed, highlighting potential secondary pathways that exacerbate mutagenesis. Understanding these additional contributors may unlock new molecular targets for therapeutic intervention aimed at halting tumor progression at an earlier stage.

The clinical implications of these discoveries are profound. By delineating the full spectrum of mutagenic processes active in CMMRD, clinicians gain tools to better predict tumor behavior and patient prognosis. For instance, tumors showing extensive polymerase slippage mutations combined with APOBEC activity might respond differently to immunotherapies or checkpoint inhibitors than tumors dominated by exogenous mutagens. Moreover, characterizing mutational signatures can aid in distinguishing between germline and somatic mutation patterns, informing genetic counseling and cascade testing in affected families.

This research also underscores the necessity for vigilance in cancer surveillance protocols for individuals with CMMRD. The dynamic nature of the mutational landscape, marked by bursts of mutational activity, may necessitate more frequent and sensitive screening approaches. Early detection of tumors at stages when they harbor specific mutational patterns could increase the efficacy of targeted therapies and improve survival outcomes. In addition, the work advocates for implementing preventive measures focusing on reducing exposure to environmental mutagens known to act in concert with genetic vulnerabilities.

Importantly, the study paves the way for personalized medicine strategies centered on mutational signature analysis. Beyond CMMRD, mismatch repair deficiency is a hallmark in a subset of sporadic cancers, and the analytical techniques pioneered here could be adapted for broader clinical use. Monitoring the evolution of mutational signatures during treatment may help identify emerging resistance mechanisms and guide therapy adjustments in real time, heralding a new era of precision oncology.

From a research perspective, the work invites further exploration into the mechanistic basis of each identified mutational process. Dissecting how specific DNA repair pathways interact or fail under CMMRD conditions could reveal novel targets for pharmacologic restoration of genomic integrity. Additionally, expanding the cohort size and integrating multi-omics data, including transcriptomics and epigenomics, could enrich our understanding of the tumor microenvironment’s role in shaping mutational landscapes.

The interdisciplinary approach combining clinical data, molecular biology, computational genomics, and bioinformatics exemplifies the future direction of cancer research. By harnessing vast genomic datasets and sophisticated analytical tools, this study charts a promising path toward unraveling the complexities of hereditary cancer syndromes. The collaborative efforts also highlight the value of open data sharing and methodological transparency to accelerate discoveries and translate them into clinical practice.

Looking ahead, the potential integration of these mutational insights into therapeutic development is particularly exciting. Agents that specifically target pathways activated in response to mismatch repair deficiency or counteract the effects of hypermutagenesis might revolutionize treatment paradigms. Moreover, better understanding of mutagenic processes could inform combination therapies that pair DNA repair-targeted drugs with immune modulators, exploiting the high neoantigen load typical of these tumors.

Ultimately, the work by Weijers and colleagues represents a significant leap forward in cancer biology. By peeling back the layers of mutational complexity in CMMRD tumors, it not only advances fundamental science but also has direct ramifications for patient care. As genetically defined cancer subsets continue to be identified, studies like this will be instrumental in translating genomic knowledge into tangible health benefits, fulfilling the promise of precision oncology in the fight against hereditary cancer.

Subject of Research: Constitutional mismatch repair deficiency (CMMRD) and its influence on tumor mutational patterns

Article Title: Unraveling mutagenic processes influencing the tumor mutational patterns of individuals with constitutional mismatch repair deficiency

Article References:
Weijers, D.D., Hinić, S., Kroeze, E. et al. Unraveling mutagenic processes influencing the tumor mutational patterns of individuals with constitutional mismatch repair deficiency. Nat Commun 16, 4459 (2025). https://doi.org/10.1038/s41467-025-59775-2

Image Credits: AI Generated